Effect of sodium–glucose transporter 2 inhibitor empagliflozin on proteinuria and kidney function progression in patients with non-diabetic glomerulonephritis: a pilot superiority randomized controlled trial

• Published in: International urology and nephrology Vol. 55; no. 9; pp. 2321 - 2326
• Main Authors: Hammad, Hany, Shaaban, Asmaa, Philips, Mariana Victor, Fayed, Ahmed, Abdelaziz, Tarek Samy
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.09.2023; Springer Nature B.V
• Subjects: Antidiabetics; Creatinine; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 2 - drug therapy; Double-Blind Method; Epidermal growth factor receptors; Glomerular Filtration Rate; Glomerulonephritis; Glomerulonephritis - complications; Glomerulonephritis - drug therapy; Glucose transporter; Humans; Immunosuppression; Kidney; Kidney diseases; Medicine; Medicine & Public Health; Nephrology; Nephrology - Original Paper; Placebos; Proteinuria; Proteinuria - drug therapy; Proteinuria - etiology; Remission; Sodium-glucose cotransporter; Sodium-Glucose Transporter 2 Inhibitors - pharmacology; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Statistical analysis; Treatment Outcome; Urology; Glomerulonephritis; Empagliflozin; Sodium–glucose transporter inhibitors; Diabetes mellitus; Proteinuria
• ISSN: 1573-2584; 0301-1623; 1573-2584
• DOI: 10.1007/s11255-023-03539-8

Background Amelioration of proteinuria is one of main treatment targets in patients with glomerulonephritis, yet the remission rates are suboptimal. Aim of the study To examine the effect of the sodium–glucose transporter 2 inhibitor (empagliflozin) on proteinuria and kidney function progression, in patients with glomerulonephritis not due to diabetic kidney diseases. Subjects and methods Fifty patients were recruited. The entry criteria were diagnosis of glomerulonephritis, and proteinuria (proteinuria ≥ 500 mg⁄g) in spite of the use of the maximal tolerated dose of RAAS blocking agents together with specific immunosuppression treatment regimens. Group 1 (Empagliflozin arm): 25 patients who received 25 mg of empagliflozin once daily for 3 months as add-on to their regular treatment protocol (RAAS blockers and immunosuppression). Group 2 (Placebo arm): 25 patients treated with RAAS blockers and immunosuppression. The primary efficacy endpoints were the change in creatinine eGFR, and proteinuria 3 months after starting treatment. Results Progression of proteinuria was lower with empagliflozin as compared to placebo (odds ratio, 0.65; 95% CI, 0.55 to 0.72, p  = 0.002). Decline in eGFR was lower with empagliflozin as compared to placebo; however, this was statistically not significant (odds ratio, 0.84; 95% CI, 0.82 to 1.2, p  = .31). The percentage change in proteinuria was greater with empagliflozin as compared to placebo (median, − 77 (− 97–105) vs − 48 (− 80–117). Conclusion Empagliflozin has a favorable effect on amelioration of proteinuria in patients with glomerulonephritis. Empagliflozin has tendency to preserve kidney function in patients with glomerulonephritis as compared to placebo; however, longer term studies are required.